Clinical trial NCT03840174: Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003)
Official title: A Phase I Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of V160 (Human Cytomegalovirus Vaccine) in Healthy Japanese Men
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Cytomegalovirus Infections
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2019-02-15
Enrollment: 18
Sex: MALE
Minimum age (years): 20
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of the study is to assess the safety and tolerability of a 3-dose regimen of V160 administered by intramuscular (IM) injection in healthy Japanese male participants by cytomegalovirus (CMV) serostatus. There is no formal hypothesis.


Eligibility criteria: Inclusion Criteria:

* Healthy based on medical history and physical examination
* Serologically confirmed to be CMV seropositive or CMV seronegative at Visit 1
* If of reproductive potential, agrees to the following from randomization through at least 4 weeks after the last dose of V160-/placebo (from Day 1 through Month 7): 1) practice abstinence from heterosexual activity and remain abstinent, or 2) use contraception unless confirmed to be azoospermic as detailed in the protocol

Exclusion Criteria:

* History of any allergic reaction or anaphylactic reaction to any vaccine component that required medical intervention
* Plans donation of sperm any time from signing the informed consent through 1 month after receiving the last dose of study drug
* Is currently immunocompromised or has been diagnosed as having a congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition that requires immunosuppressive medication.
* Has a condition in which repeated venipuncture or injections post more than minimal risk for the participant, such as hemophilia, thrombocytopenia, other severe coagulation disorders, or significantly impaired venous access
* Has major psychiatric illness including: any history or schizophrenia or severe psychosis, bipolar disorder requiring therapy, or suicidal ideation within 3 years.
* Has previously received any CMV vaccine
* Had any live virus vaccine administered or scheduled to be administered in the period from 4 weeks prior to, and 4 weeks following receipt of study drug
* Had any inactivated vaccine administered or scheduled within the period from 14 days prior to, through 14 days following study drug
* Had administration of any immune globulin or blood product within 90 days prior to injection with study drug or scheduled within 30 days thereafter
* Has received systemic corticosteroids (equivalent of ≥2 mg/kg total daily dose of prednisone or ≥20 mg/d for persons weighing \>10 kg) for ≥14 consecutive days and has not completed treatment at least 30 days prior to study entry
* Has received systemic corticosteroids exceeding physiologic replacement doses (≈5 mg/d prednisone equivalent) within 14 days prior to the first vaccination (participants using inhaled, nasal, or topical steroids are considered eligible for the study)
* Has received any anti-viral agent (e.g. letermovir, ganciclovir, valganciclovir, foscarnet, and valacyclovir) with proven or potential activity against CMV 14 days prior to vaccination or is likely to receive such an agent within 14 days after vaccination

  * Receiving or has received in the year prior to enrollment immunosuppressive therapies including but not limited to rapamycin (also sirolimus), tacrolimus (also FK-506), or other therapies used for solid organ/cell transplant, radiation therapy, immunosuppressive/cytotoxic immunotherapy, chemotherapy and other immunosuppressive therapies known to interfere with the immune response. Topical tacrolimus is allowed provided that it is not used within 14 days prior to, or 14 days following study drug
* Has participated in another clinical trial in the past 4 weeks, or plans to participate in a treatment-based trial or a trial in which an invasive procedure is to be performed while enrolled in this trial.

Primary outcomes:
measure: Percentage of Participants With a Solicited Injection-site Adverse Event (AE)
timeFrame: Up to 5 days after each vaccination
measure: Percentage of Participants With a Solicited Systemic Adverse Event (AE)
timeFrame: Up to 14 days after each vaccination
measure: Percentage of Participants With a Vaccine-related Serious Adverse Event (SAE)
timeFrame: Up to 14 days after each vaccination
Secondary outcomes:
measure: Geometric Mean Titer (GMT) of CMV-specific Neutralizing Antibody (NAb)
timeFrame: 1 month after third vaccination (at 7 months)
measure: Number of Participants With Viral Detection of V160 in Plasma
timeFrame: Day 1 (predose, at dosing, and 3 hours postdose), Day 3, Day 7, and Day 14
measure: Number of Participants With Wild-Type CMV Detection in Urine and Saliva
timeFrame: Day 1 (predose), 3, 7, and 14 and Months 2, 6, and 7
measure: Number of Participants With Viral Detection of V160 in Injection-site Swab and Adhesive Tape Swab
timeFrame: Day 1: 0, 10, 20, and 30 minutes postvaccination
Other outcomes:
Locations:
city: Fukuoka
country: Japan
facility: Souseikai PS Clinic ( Site 0001)
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Director
role: STUDY_DIRECTOR
References:
citation: Murata S, Oshima N, Iwasa T, Fukao Y, Sawata M. Safety, Tolerability, and Immunogenicity of V160, a Conditionally Replication-Defective Cytomegalovirus Vaccine, in Healthy Japanese Men in a Randomized, Controlled Phase 1 Study. Antibodies (Basel). 2023 Mar 10;12(1):22. doi: 10.3390/antib12010022.